LUCID DIAGNOSTICS INC.(LUCD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LUCD LUCID DIAGNOSTICS INC.

Market Closed 12-20 16:00:00 EST

0.7810

+0.0101

+1.31%

盘后0.7800

-0.0010-0.13%

19:47 EST

High0.7999	Low0.7800	Vol374.39K
Open0.7900	D1 Closing0.7709	Amplitude2.58%
Mkt Cap46.35M	Tradable Cap18.96M	Total Shares59.34M
T/O294.81K	T/O Rate1.54%	Tradable Shares24.28M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"LUCD","market":"US","secType":"STK","nameCN":"LUCID DIAGNOSTICS INC.","latestPrice":0.781,"timestamp":1734728400000,"preClose":0.7709,"halted":0,"volume":374390,"hourTrading":{"tag":"盘后","latestPrice":0.78,"preClose":0.781,"latestTime":"19:47 EST","volume":1656,"amount":1312.5292,"timestamp":1734742029708},"delay":0,"floatShares":24282399,"shares":59342500,"eps":-1.125179,"marketStatus":"Market Closed","change":0.0101,"latestTime":"12-20 16:00:00 EST","open":0.79,"high":0.7999,"low":0.78,"amount":294812.132574,"amplitude":0.025814,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.125179,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1734944400000},"marketStatusCode":7,"adr":0,"listingDate":1634184000000,"exchange":"NASDAQ","adjPreClose":0.7709,"preHourTrading":{"tag":"盘前","latestPrice":0.8,"preClose":0.7709,"latestTime":"09:24 EST","volume":3888,"amount":3101.702272,"timestamp":1734704681346},"postHourTrading":{"tag":"盘后","latestPrice":0.78,"preClose":0.781,"latestTime":"19:47 EST","volume":1656,"amount":1312.5292,"timestamp":1734742029708},"volumeRatio":0.7179093246136462},"requestUrl":"/m/hq/s/LUCD","defaultTab":"news","newsList":[{"id":"2492120530","title":"Lucid Diagnostics partners for esophageal precancer detection for firefighters","url":"https://stock-news.laohu8.com/highlight/detail?id=2492120530","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492120530?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:11","pubTimestamp":1734613871,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics (LUCD), a subsidiary of PAVmed (PAVM), has entered into a strategic partnership with VITALExam, a comprehensive medical care prov...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lucid-diagnostics-partners-for-esophageal-precancer-detection-for-firefighters?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lucid-diagnostics-partners-for-esophageal-precancer-detection-for-firefighters?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4555","BK4596","LUCD","BK4082","BK4099","PAVM","BK4551","LCID"],"gpt_icon":0},{"id":"2492412076","title":"Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters","url":"https://stock-news.laohu8.com/highlight/detail?id=2492412076","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492412076?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:01","pubTimestamp":1734613260,"startTime":"0","endTime":"0","summary":"Partnership launched with fully-contracted #CheckYourFoodTube Precancer Testing Event for Tuscaloosa firefighters. NEW YORK, Dec. 19, 2024 /PRNewswire/ -- Lucid Diagnostics Inc., a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. , today announced that it has entered into a strategic partnership with VITALExam LLC , a comprehensive medical care provider for first responders founded by Chief Executive Officer Marci Vitale, DNP, FNP-BC, AGACNP-BC, to enhance access to Lucid's EsoGuard Esophageal DNA Testfor firefighters at risk for esophageal precancer. Lucid and VITALExam launched the partnership with a fully-contracted #CheckYourFoodTube Precancer Testing Event at Tuscaloosa Fire Rescuein Tuscaloosa, AL, as part of Lucid's expanded direct contracting initiativefocused on driving near-term EsoGuard revenue.VITALExam is a comprehensive medical care provider dedicated to optimizing the wellness of first responders. Founded by Dr. Vitale, the co","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/cNb4vYrfvYmKz8.h.dXgbA--~B/aD0xMDc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/9ee0d0ae0eda5368bcc0b17e848d707c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/cNb4vYrfvYmKz8.h.dXgbA--~B/aD0xMDc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/9ee0d0ae0eda5368bcc0b17e848d707c"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/lucid-diagnostics-partners-vitalexam-enhance-130100161.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lucid-diagnostics-partners-vitalexam-enhance-130100161.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4099","BK4596","LUCD","BK4551","BK4082","BK4555","PAVMZ","PAVM"],"gpt_icon":1},{"id":"2490302854","title":"Lucid announces publication on EsoGuard in peer-reviewed journal Medicina","url":"https://stock-news.laohu8.com/highlight/detail?id=2490302854","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490302854?lang=en_us&edition=fundamental","pubTime":"2024-12-11 21:11","pubTimestamp":1733922690,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics (LUCD) and subsidiary of PAVmed (PAVM), announced that the manuscript for its CLinical Utility of EsoGuard, or CLUE, study has be...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lucid-announces-publication-on-esoguard-in-peer-reviewed-journal-medicina?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lucid-announces-publication-on-esoguard-in-peer-reviewed-journal-medicina?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4551","BK4596","BK4099","BK4555","BK4082","LUCD","PAVM"],"gpt_icon":0},{"id":"2490516908","title":"Prospective Clinical Utility Study of Lucid Diagnostics' Esoguard® Esophageal DNA Test Accepted for Peer-Reviewed Publication","url":"https://stock-news.laohu8.com/highlight/detail?id=2490516908","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490516908?lang=en_us&edition=fundamental","pubTime":"2024-12-11 21:01","pubTimestamp":1733922063,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241211:nTUA87CKMH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4551","PAVM","BK4555","LUCD","BK4082","LCID","BK4596","BK4099"],"gpt_icon":0},{"id":"2490514948","title":"Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication","url":"https://stock-news.laohu8.com/highlight/detail?id=2490514948","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490514948?lang=en_us&edition=fundamental","pubTime":"2024-12-11 21:01","pubTimestamp":1733922060,"startTime":"0","endTime":"0","summary":"Study demonstrates outstanding clinical utility including an exceptionally high 85% patient compliance with referral to confirmatory upper endoscopy following EsoGuard esophageal precancer testing. NEW YORK, Dec. 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc., a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. , today announced that the manuscript for its CLinical Utility of EsoGuard  study has been accepted for publication in the peer-reviewed journal Medicina. This is the fourth peer-reviewed publication presenting outstanding clinical utility data for the EsoGuard Esophageal DNA Test. In addition to demonstrating near-perfect provider decision impact, consistent with previous EsoGuard clinical utility studies, the study documented an exceptionally high 85% patient compliance with referral to confirmatory upper endoscopy  following EsoGuard esophageal precancer testing in a real-world clinical setting.The prospective, multicenter CLUE stu","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/cNb4vYrfvYmKz8.h.dXgbA--~B/aD0xMDc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/9ee0d0ae0eda5368bcc0b17e848d707c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/cNb4vYrfvYmKz8.h.dXgbA--~B/aD0xMDc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/9ee0d0ae0eda5368bcc0b17e848d707c"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/prospective-clinical-utility-study-lucid-130100766.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/prospective-clinical-utility-study-lucid-130100766.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0444973449.USD","BK4596","LU0823414478.USD","PAVM","BK4082","BK4139","LU0476273544.USD","BK4555","LU0957808578.USD","LU2249611893.SGD","BK4099","BK4551","BK4588","PAVMZ","BE","BK4109","BK4541","LU1815336760.USD","LU2294711713.HKD","DNA","BK4182","LU1642822529.SGD","LU0823414551.USD","LUCD","LU2357125470.USD","LU2506951792.HKD","BK4585","LU0444971666.USD"],"gpt_icon":1},{"id":"2488912711","title":"Lucid Diagnostics completes convertible debt refinancing","url":"https://stock-news.laohu8.com/highlight/detail?id=2488912711","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488912711?lang=en_us&edition=fundamental","pubTime":"2024-12-03 21:12","pubTimestamp":1733231539,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics (LUCD), a subsidiary of PAVmed (PAVM), announced the successful completion of a convertible debt refinancing transaction that str...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lucid-diagnostics-completes-convertible-debt-refinancing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lucid-diagnostics-completes-convertible-debt-refinancing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PAVM","LCID","BK4596","BK4082","BK4551","BK4099","BK4555","LUCD"],"gpt_icon":0},{"id":"2488914178","title":"Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2488914178","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488914178?lang=en_us&edition=fundamental","pubTime":"2024-12-03 21:01","pubTimestamp":1733230863,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241203:nTUAP602P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PAVM","BK4082","LUCD"],"gpt_icon":0},{"id":"2488491441","title":"Press Release: Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2488491441","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488491441?lang=en_us&edition=fundamental","pubTime":"2024-12-03 21:01","pubTimestamp":1733230860,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones. New convertible debt financing with existing long-term equity shareholders yields $18M in net cash proceeds after paying off existing convertible debt. \"We believe that this debt refinancing, which is a strong vote of confidence in Lucid's technology and commercial potential by long-term Lucid shareholders, enhances shareholder value in two critical ways,\" said Lishan Aklog, M.D., Chairman and Chief Executive Officer of Lucid. \"The net proceeds increase our pro forma cash as of the end of the third quarter to approximately $33 million, providing us with sufficient cash to get us past key reimbursement milestones which we have previously outlined. This new convertible debt is held by long-term investors and has terms which are designed to keep shares out of the market.\". This press release includes forward-looking statements that involve risk and unc","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4082","BK4555","LUCD","BK4596","BK4232","BK4099","NQmain","R","PAVM","LCID","BK4022"],"gpt_icon":0},{"id":"2487916518","title":"Lucid Diagnostics’ Strategic Financial Maneuvering and Agreements","url":"https://stock-news.laohu8.com/highlight/detail?id=2487916518","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487916518?lang=en_us&edition=fundamental","pubTime":"2024-11-30 05:49","pubTimestamp":1732916943,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics ( ($LUCD) ) has issued an announcement. Lucid Diagnostics Inc. recently secured $21.95 million through the sale of Senior Secured...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lucid-diagnostics-strategic-financial-maneuvering-and-agreements?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lucid-diagnostics-strategic-financial-maneuvering-and-agreements?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4596","BK4551","BK4082","LUCD","BK4555","LCID","BK4099"],"gpt_icon":0},{"id":"2484152551","title":"Lucid Diagnostics submits clinical evidence for EsoGuard Esophagea DNA test","url":"https://stock-news.laohu8.com/highlight/detail?id=2484152551","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484152551?lang=en_us&edition=fundamental","pubTime":"2024-11-20 21:00","pubTimestamp":1732107621,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics (LUCD), a subsidiary of PAVmed (PAVM), announced that it has submitted its complete clinical evidence package for its EsoGuard Es...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lucid-diagnostics-submits-clinical-evidence-for-esoguard-esophagea-dna-test?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lucid-diagnostics-submits-clinical-evidence-for-esoguard-esophagea-dna-test?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4555","BK4596","BK4551","PAVM","BK4109","BK4099","LUCD","BK4082","DNA"],"gpt_icon":0},{"id":"2484115668","title":"Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2484115668","media":"PR Newswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484115668?lang=en_us&edition=fundamental","pubTime":"2024-11-20 20:56","pubTimestamp":1732107360,"startTime":"0","endTime":"0","summary":"\"This submission is the culmination of many years of persistent hard work by our team and our many clinical research partners, and represents perhaps the most important milestone in Lucid's history,\" said Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer. \"We believe the data in this package strongly supports EsoGuard's clinical validity, utility, and analytical accuracy, aligning with the MolDX criteria for coverage as outlined in the LCD. The clinical validity data, in particular, demonstrates EsoGuard's unprecedented precancer detection performance across all studies. We look forward to the opportunity to expand access to EsoGuard precancer testing to all at-risk Medicare beneficiaries.\". The EsoGuard clinical evidence package includes six new peer-reviewed publications: three clinical validation studies , two clinical utility studies, and one analytical validation study. The current LCD provides clear coverage criteria consistent with the American College of Gastroen","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/cNb4vYrfvYmKz8.h.dXgbA--~B/aD0xMDc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/9ee0d0ae0eda5368bcc0b17e848d707c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/cNb4vYrfvYmKz8.h.dXgbA--~B/aD0xMDc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/9ee0d0ae0eda5368bcc0b17e848d707c"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/lucid-diagnostics-submits-clinical-evidence-125600161.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lucid-diagnostics-submits-clinical-evidence-125600161.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4555","LU1894683264.USD","BK4231","CMS","BK4588","BK4551","LU1894683348.USD","MAC","BK4208","BK4109","BK4596","BK4080","LU2637428348.USD","BK4585","BK4099","BK4139","BK4082","DNA","LUCD","LU2346227817.USD","PAVMZ","PAVM"],"gpt_icon":1},{"id":"2484428627","title":"Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2484428627","media":"PR Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484428627?lang=en_us&edition=fundamental","pubTime":"2024-11-18 21:15","pubTimestamp":1731935700,"startTime":"0","endTime":"0","summary":"NEW YORK, Nov. 18, 2024 /PRNewswire/ -- Lucid Diagnostics Inc., a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. , today announced that company management will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 21, 2024 at 1:30 p.m. ET.Live and replay webcasts may be accessed on the investor relations section of the Company's website at ir.luciddx.com. The webcast will be archived and available for replay for at least 30 days after the event.For more information about Lucid, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/cNb4vYrfvYmKz8.h.dXgbA--~B/aD0xMDc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/9ee0d0ae0eda5368bcc0b17e848d707c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/cNb4vYrfvYmKz8.h.dXgbA--~B/aD0xMDc7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/9ee0d0ae0eda5368bcc0b17e848d707c"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/lucid-diagnostics-present-canaccord-genuity-131500357.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lucid-diagnostics-present-canaccord-genuity-131500357.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4082","LUCD","BK4551","FET","BK4179","PAVMZ","BK4555","BK4596","BK4099","PAVM"],"gpt_icon":1},{"id":"2483919329","title":"Q3 2024 PAVmed Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2483919329","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483919329?lang=en_us&edition=fundamental","pubTime":"2024-11-15 19:23","pubTimestamp":1731669792,"startTime":"0","endTime":"0","summary":"Lishan Aklog; Chairman of the Board, Chief Executive Officer; PAVmed Inc. Dennis Mcgrath; President, Chief Financial Officer; PAVmed Inc. Good morning, and welcome to the PAVmed's third-quarter 2024 business update conference call.  Please note this event is being recorded. I would now like to turn the conference over to Matt Riley, PAVmed Director of Investor Relations. Please go ahead.Thank you, Matt, and good morning, everyone. Thank you for joining our quarterly update call. As always, I'd like to thank our long-term shareholders for your ongoing support and commitment. . Before we delve into our recent operational highlights, I'd like to make a few high-level points. This has been a transformational quarter for PAVmed. Over the last couple of quarters, we've taken several critical steps related to PAVmed's corporate structure and balance sheet. This strategic transformation, which is now essentially complete, put PAVmed in the strong position to fulfill its mission on behalf of it","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q3-2024-pavmed-inc-earnings-112312780.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PAVMZ","PAVM","LUCD"],"gpt_icon":0},{"id":"2483312814","title":"PAVmed Inc (PAVM) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Restructuring","url":"https://stock-news.laohu8.com/highlight/detail?id=2483312814","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483312814?lang=en_us&edition=fundamental","pubTime":"2024-11-15 15:09","pubTimestamp":1731654567,"startTime":"0","endTime":"0","summary":"Revenue: Record revenue with a 20% increase quarter-on-quarter.Net Income: GAAP net income of $61 million due to deconsolidation adjustments.Earnings Per Share : Positive primary EPS of $6.43 and diluted EPS of $1.44.Cash Burn Rate: PAVmed's stand-alone burn rate for the third quarter is about breakeven.Operating Expenses: Total non-GAAP operating expenses of $10.1 million for the third quarter.Convertible Debt Restructuring: Agreement to exchange $25 million of existing obligations for Series C convertible preferred stock.NIH Grant: Received a $1.8 million NIH grant for Veris Health.Lucid Diagnostics Deconsolidation: Deconsolidation completed on September 10, reducing shareholder deficit by half.Lucid Share Ownership: PAVmed's balance sheet now includes $25.5 million market value of its 31.3 million Lucid shares.PAVmed Inc  reported a transformational quarter with strategic steps to strengthen its corporate structure and balance sheet.PAVmed Inc  restructured its convertible debt, all","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/U9uX6VnE_PEgi4QMFULLUw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/79f07f9d8c152373b559faa8542cf2a4","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/U9uX6VnE_PEgi4QMFULLUw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/79f07f9d8c152373b559faa8542cf2a4"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pavmed-inc-pavm-q3-2024-070927445.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PAVMZ","PAVM","LUCD"],"gpt_icon":0},{"id":"2483870227","title":"PAVmed: Ongoing Initiatives Position PAVmed to Preserve Nasdaq Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2483870227","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483870227?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:01","pubTimestamp":1731589263,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nTUA6CSQCW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","PAVM","LUCD"],"gpt_icon":0},{"id":"2483870090","title":"PAVmed Inc: Qtrly Shr Loss $0.54","url":"https://stock-news.laohu8.com/highlight/detail?id=2483870090","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483870090?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:01","pubTimestamp":1731589263,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nTUA6CSQCW:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","PAVM","LUCD"],"gpt_icon":0},{"id":"2483845870","title":"PAVmed Provides Business Update and Third Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483845870","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483845870?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:01","pubTimestamp":1731589260,"startTime":"0","endTime":"0","summary":"Veris Health completes pilot program with The Ohio State's James Cancer Hospital and continues pursuit of financing to relaunch development of implantable monitor. Ongoing initiatives position PAVmed to preserve Nasdaq listing. Conference call and webcast to be held today, November 14th at 8:30 AM EST. NEW YORK, Nov. 14, 2024 /PRNewswire/ -- PAVmed Inc. , a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc.   and Veris Health Inc. , and presented financial results for the Company for the three months ended September 30, 2024.Lucid reportedthat 3Q24 EsoGuard Esophageal DNA Test revenue was $1.2M, which represents a single-quarter record and 20 percent increase sequentially from 2Q24.Lucid performed 2,787 commercial EsoGuard tests in 3Q24. Additionally, in October the lab performed a single-month record of more than ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FWK3H6ghAnEr1SIDWzsHtQ--~B/aD04MTt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/b33818e0ad32f6b512ca93166f23ff80","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FWK3H6ghAnEr1SIDWzsHtQ--~B/aD04MTt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/b33818e0ad32f6b512ca93166f23ff80"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/pavmed-provides-business-third-quarter-130100984.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pavmed-provides-business-third-quarter-130100984.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QLD","TQQQ","NQmain","PSQ","BK4082","BK4551","PAVMZ","BK4099",".IXIC","BK4555","QID","BK4596","MNQmain","PAVM","LUCD","SQQQ"],"gpt_icon":1},{"id":"2483826983","title":"Lucid Diagnostics Price Target Maintained With a $2.50/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2483826983","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483826983?lang=en_us&edition=fundamental","pubTime":"2024-11-14 17:51","pubTimestamp":1731577860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LUCD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 14, 2024 04:51 ET (09:51 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LUCD"],"gpt_icon":0},{"id":"2483841723","title":"Lucid Diagnostics Inc (LUCD) Q3 2024 Earnings Call Highlights: Record Revenue Growth Amid ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2483841723","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483841723?lang=en_us&edition=fundamental","pubTime":"2024-11-14 15:09","pubTimestamp":1731568169,"startTime":"0","endTime":"0","summary":"Revenue: $1.2 million, a 20% increase quarter-on-quarter and a 50% increase year-over-year.Test Volume: 2,787 tests conducted in the third quarter.Cash at Quarter End: $14.5 million as of September 30th.Convertible Debt: Notice given to redeem the remainder of the outstanding note.Shares Outstanding: Approximately 59.3 million shares as of the latest update.Non-GAAP Net Loss per Share: $0.20, consistent with previous quarters.Operating Expenses : $11.3 million for the third quarter.Pro Forma Revenue from Submitted Claims: Nearly $7 million.Cash Increase from New Investments: Expected to increase cash by about $13.2 million net of payoff.GuruFocus has detected 4 Warning Signs with LUCD.Lucid Diagnostics Inc  reported a 20% increase in quarterly revenue, reaching a record $1.2 million for the third quarter.Lucid Diagnostics Inc  has expanded its direct contracting initiatives, focusing on securing agreements with self-insured entities to drive revenue.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lucid-diagnostics-inc-lucd-q3-070929580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LUCD"],"gpt_icon":1},{"id":"2483880555","title":"Lucid Diagnostics Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2483880555","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483880555?lang=en_us&edition=fundamental","pubTime":"2024-11-13 23:27","pubTimestamp":1731511666,"startTime":"0","endTime":"0","summary":"Lucid Diagnostics Inc reports results for the quarter ended September 30 - Earnings SummaryLucid Diagnostics Inc LUCD.OQ reported a quarterly adjusted loss of 25 cents per share for the quarter ended ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nL8N3MK236:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LUCD","PAVM"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.luciddx.com","stockEarnings":[{"period":"1week","weight":-0.0056},{"period":"1month","weight":-0.219},{"period":"3month","weight":-0.0532},{"period":"6month","weight":0.1271},{"period":"1year","weight":-0.4299},{"period":"ytd","weight":-0.4461}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.145712},{"month":2,"riseRate":0.666667,"avgChangeRate":0.024},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.137912},{"month":4,"riseRate":0.666667,"avgChangeRate":-0.069847},{"month":5,"riseRate":0.333333,"avgChangeRate":0.021747},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.042921},{"month":7,"riseRate":0.666667,"avgChangeRate":0.092072},{"month":8,"riseRate":0.666667,"avgChangeRate":-0.051917},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.172317},{"month":10,"riseRate":1,"avgChangeRate":0.182141},{"month":11,"riseRate":0.5,"avgChangeRate":-0.019817},{"month":12,"riseRate":0,"avgChangeRate":-0.209537}],"exchange":"NASDAQ","name":"LUCID DIAGNOSTICS INC.","nameEN":"LUCID DIAGNOSTICS INC."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"LUCID DIAGNOSTICS INC.(LUCD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest LUCID DIAGNOSTICS INC.(LUCD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"LUCID DIAGNOSTICS INC.,LUCD,LUCID DIAGNOSTICS INC.股票,LUCID DIAGNOSTICS INC.股票老虎,LUCID DIAGNOSTICS INC.股票老虎国际,LUCID DIAGNOSTICS INC.行情,LUCID DIAGNOSTICS INC.股票行情,LUCID DIAGNOSTICS INC.股价,LUCID DIAGNOSTICS INC.股市,LUCID DIAGNOSTICS INC.股票价格,LUCID DIAGNOSTICS INC.股票交易,LUCID DIAGNOSTICS INC.股票购买,LUCID DIAGNOSTICS INC.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"LUCID DIAGNOSTICS INC.(LUCD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest LUCID DIAGNOSTICS INC.(LUCD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}